Wegovy口服藥營收達54億丹麥克朗,諾和諾德上調2026年展望

Novo Nordisk raises 2026 outlook as Wegovy pill sales reach 5.4 billion kroner

Updated at: November 5, 2026 at 01:18 AM

諾和諾德於11月4日上調2026年展ㄓㄢˇ望ㄨㄤˋ,主因是肥胖症治療藥物銷售較強。這家丹麥藥廠目前預期,排除匯率變動後,全年調整後營收及調整後營業利益的變化幅度,均介於負2%至正2%。

Novo Nordisk raised its 2026 outlook on November 4 after stronger sales of its obesity treatments. The Danish drugmaker now expects adjusted sales and adjusted operating profit each to change by between minus 2 and plus 2 percent at constant exchange rates over the full year.

noun展望

第三季營收達791.95億丹麥克朗,按固定匯率成長4%。公司表示,美國與國際業務的GLP-1產品需ㄒㄩ求ㄑㄧㄡˊ都增加,尤其是肥胖症照護相關產品。

Third-quarter sales reached 79.195 billion Danish kroner, up 4 percent at constant exchange rates. The company said demand for GLP-1 products increased across both its US and international businesses, particularly in obesity care.

noun需求

Wegovy口服藥在這一季創造53.94億克朗營收。截至9月底,已在美國、阿拉伯聯合大公國、英國及德國上ㄕㄤˋ市ㄕˋ;之後再增加四國,使上ㄕㄤˋ市ㄕˋ市場總數達八個。

The Wegovy pill generated 5.394 billion kroner during the quarter. By the end of September it had launched in the United States, United Arab Emirates, Britain and Germany. Four more launches subsequently brought the number of markets to eight.

verb上市
verb上市

按固定匯率計算,調整後營業利益成長27%至317.20億克朗。比較基ㄐㄧ期ㄑㄧˊ受到一年前90億克朗轉型成本影響;這筆支出壓低了去年的基準數字。

Adjusted operating profit rose 27 percent to 31.720 billion kroner at constant exchange rates. The comparison benefited from 9 billion kroner of transformation costs recorded a year earlier, which had lowered the previous year’s base.

noun基期

財報列報的營業利益則反向變動,在相同匯率基礎下下降9%。其中包括87億克朗非現金減ㄐㄧㄢˇ損ㄙㄨㄣˇ費用,與一項藥物計畫及製造網絡調整有關。

Reported operating profit moved in the opposite direction, falling 9 percent on the same exchange-rate basis. It included 8.7 billion kroner in non-cash impairment charges related to a drug project and changes to the manufacturing network.

noun減損

執行長Mike Doustdar表示,公司正準備於2027年初在美國推出CagriSema,但仍須監管機關核ㄏㄜˊ准ㄓㄨㄣˇ。擴大藥物可近性及持續在國際市場上ㄕㄤˋ市ㄕˋ,仍是公司計畫的一部分。

Chief executive Mike Doustdar said the company was preparing for a US launch of CagriSema in early 2027, subject to regulatory approval. Broader access to medicines and continued international launches remain part of its plans.

verb核准
verb上市
🎉

End of article

You read 6 focus sentences.

Challenge Mode

Comprehension Questions

新的全年調整後成長區間為何?

✓

Correct Choice

負2%至正2%

固定匯率下,季度營收成長多少?

✓

Correct Choice

4%

後續上ㄕㄤˋ市ㄕˋ後,Wegovy口服藥進入多少市場?

✓

Correct Choice

八個

什麼因素有利調整後利益的比較?

✓

Correct Choice

去年有大筆轉型成本

若獲核ㄏㄜˊ准ㄓㄨㄣˇ,CagriSema預定何時在美國上ㄕㄤˋ市ㄕˋ?

✓

Correct Choice

2027年初

Ringoo Icon

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.